These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 34868078)

  • 1. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
    Qi F; Liu F; Gao L
    Front Immunol; 2021; 12():790125. PubMed ID: 34868078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
    Relke N; Gooderham M
    J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
    Niu C; Xie H; Aisa HA
    Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic Th2 Cytokine Profile Skewing by IFN-γ-Responding Vitiligo Fibroblasts via CCL2/CCL8.
    Jin R; Zhou M; Lin F; Xu W; Xu A
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitors for the treatment of vitiligo.
    Inoue S; Suzuki T; Sano S; Katayama I
    J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
    Sardana K; Muddebihal A; Khurana A
    Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
    Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
    Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome.
    Charras A; Arvaniti P; Le Dantec C; Arleevskaya MI; Zachou K; Dalekos GN; Bordon A; Renaudineau Y
    Clin Rev Allergy Immunol; 2020 Apr; 58(2):182-193. PubMed ID: 31165348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
    Ryguła I; Pikiewicz W; Kaminiów K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK Inhibitors: Prospects in Connective Tissue Diseases.
    You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Janus kinase inhibitors for skin disorders].
    Solimani F; Ghoreschi K
    Dermatologie (Heidelb); 2024 Oct; 75(10):781-790. PubMed ID: 39212722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
    Muddebihal A; Khurana A; Sardana K
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo.
    Chang Y; Kang P; Cui T; Guo W; Zhang W; Du P; Yi X; Guo S; Gao T; Li C; Li S
    J Transl Med; 2023 Jul; 21(1):434. PubMed ID: 37403086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.